PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26977874-3	2016	(2016) report that nelfinavir suppresses MITF expression induced by MAPK pathway inhibition in melanoma cells and sensitizes melanoma cells with NRAS or BRAF plus NRAS mutations to MEK inhibitors.	Nelfinavir	19-29	NRAS proto-oncogene, GTPase	Homo sapiens	145-149	
26977879-4	2016	Nelfinavir profoundly sensitizes BRAF and NRAS mutant melanoma cells to MAPK-pathway inhibitors.	Nelfinavir	0-10	NRAS proto-oncogene, GTPase	Homo sapiens	42-46	
26977879-5	2016	Moreover, nelfinavir is effective in BRAF and NRAS mutant melanoma cells isolated from patients progressed on MAPK inhibitor (MAPKi) therapy and in BRAF/NRAS/PTEN mutant tumors.	Nelfinavir	10-20	NRAS proto-oncogene, GTPase	Homo sapiens	46-50	
26977879-5	2016	Moreover, nelfinavir is effective in BRAF and NRAS mutant melanoma cells isolated from patients progressed on MAPK inhibitor (MAPKi) therapy and in BRAF/NRAS/PTEN mutant tumors.	Nelfinavir	10-20	NRAS proto-oncogene, GTPase	Homo sapiens	153-157